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Endothelial dysfunction in peripheral arterial
disease is related to increase in plasma markers of
inflammation and severity of peripheral circulatory
impairment but not to classic risk factors and
atherosclerotic burden
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Vittorio Schiano,a and Francesco Scopacasa,b Naples, Italy
Objective: We undertook this study to evaluate in patients with peripheral arterial disease (PAD) the relationship of
endothelial dysfunction, which is directly related to progression and clinical complications of atherosclerosis, with
variables including classic risk factors, inflammation, severity of peripheral circulatory impairment, and atherosclerotic
burden.
Methods: This cross-sectional study included outpatients seen in an academic angiologic unit. Eighty-eight consecutive
patients with PAD (ankle/brachial index [ABI] < 0.90) were studied. The control group consisted of 30 age-matched
and sex-matched healthy subjects. Main outcome measures were endothelial function in the form of brachial artery
flow-mediated dilation (FMD), plasma levels of C-reactive protein (CRP) and fibrinogen, severity of PAD according to
ABI, and atherosclerotic burden, ie, atherosclerosis in one leg or in two or more other sites.
Results: Compared with patients with FMD greater than 6.2% (ie, 5th percentile of FMD in control subjects), patients
with FMD less than 6.2% had a similar prevalence of classic risk factors but higher median levels of CRP (1.6 vs 6.0mg/L;
P < .01) and fibrinogen (200 vs 374 mg/dL; P < .01). The two inflammatory markers were negatively correlated with
FMD (P < .01). ABI was higher in patients with FMD greater than 6.2% than in those with worse endothelial function
(0.72 0.15 vs 0.62 16; P< .01); there was no difference with respect to atherosclerotic burden. Multivariate analysis
showed that the association of CRP, fibrinogen, and ABI with FMD less than 6.2% was unrelated to classic risk factors.
In a second model, which included CRP, fibrinogen, and ABI, all three variables were independently related to FMD less
than 6.2%.
Conclusion: Inflammation and severity of circulatory impairment are implicated in the pathophysiology of dysfunctional
endothelium in PAD. (J Vasc Surg 2003;38:374-9.)
Peripheral arterial disease (PAD) is closely associated
with high risk for myocardial infarction and stroke.1-4 This
increased risk, which appears to be independent of classic
risk factors1,4 and is only partly explained by the expected
association of PAD with coronary and cerebrovascular dis-
ease,1,2 is strongly related to severity of PAD.1,4 Moreover,
the poor long-term prognosis of PAD is significantly asso-
ciated with elevated plasma levels of the inflammatory
markers C-reactive protein (CRP) and fibrinogen.5,6 How-
ever, the mechanisms that link severity of circulatory failure
in the affected limb and levels of acute-phase proteins to
cardiovascular risk in PAD are unclear. One of these mech-
anisms could be impairment in the functional properties of
the endothelium, which elicits a series of changes directly
related to initiation, progression, and clinical complications
of atherosclerosis.7 Endothelial function may be evaluated
by measuring the vasodilator response to pharmacologic or
physical stimuli that induce release of nitric oxide from
endothelial cells.8,9 Reduced endothelium-mediated vaso-
reactivity, as measured in the brachial artery, is associated
with classic cardiovascular risk factors, also in the absence of
overt atherosclerotic disease,10 and is related to low-grade
inflammation in patients with coronary artery disease.11,12
Moreover, it correlates well with response in the coronary
circulation13 and is linked to increased cardiovascular
risk.14,15 Therefore brachial artery vasomotor dysfunction
appears to reflect generalized endothelial dysfunction and is
a measure of susceptibility to development of atheroma.
However, data about endothelium-mediated vasodilation
in PAD are scarce16-18; thus the determinants of endothe-
lial dysfunction in PAD need to be clarified. Accordingly,
we measured endothelium-mediated vasodilation in a
group of patients with PAD to address the following ques-
tions: Is there a relationship between endothelial dysfunc-
tion, classic risk factors, and plasma markers of inflamma-
tion? Is endothelial dysfunction related to ankle/brachial
index (ABI), which is a marker of PAD severity?19 Is
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endothelial dysfunction related to atherosclerotic burden
(measured as presence of atherosclerosis in only one leg or
in two or more sites)? Given the key role of endothelial
dysfunction in atherogenesis,7 the answers to these ques-
tions may help in clarifying the mechanisms that favor
progression of atherosclerosis in a population at high car-
diovascular risk.
PATIENTS AND METHODS
This cross-sectional study included 88 consecutive pa-
tients (81 men, 7 women; ages, 64.7  10 years) in whom
PAD was diagnosed at duplex scanning on the basis of ABI
 0.90 associated with 1 or more stenoses greater than 50%
in one of the arteries supplying the legs.
The control group consisted of 30 subjects matched to
the patients for age and sex, recruited from outpatients
attending our angiologic unit for treatment of venous
insufficiency of the lower limb, hospital staff, and their
relatives. All control subjects had ABI greater than 0.90,
had no symptoms of coronary artery disease (CAD), and
had a normal electrocardiogram. Our institutional ethics
committee approved the study, and informed consent was
obtained from patients and control subjects.
Data collection. Historical and demographic infor-
mation was collected at the first visit, after which all patients
underwent complete clinical and arterial evaluation, ac-
cording to the routine protocol of our vascular laboratory.
In brief, systolic pressure in the right and left posterior tibial
arteries and the right brachial artery was measured twice
with aDoppler ultrasound scanning probe after the patients
had been resting supine for 5 minutes. The average of the
two measurements was used to evaluate ABI. The lower
ABI value of the two legs was used for correlation with
flow-mediated dilation (FMD). Then all patients under-
went echo color Doppler scanning of the abdominal aorta,
the lower limb, and the carotid arteries. Patients with no
history of CAD underwent myocardial scintigraphy to ver-
ify the presence or absence of ischemic heart disease. One
week later endothelial function was evaluated with mea-
surement of FMD of the brachial artery with a high-
resolution ultrasound system (Hewlett-Packard, Andover,
Mass), according to recent guidelines.20 In brief, FMDwas
assessed by measuring the change in brachial artery diame-
ter after 60 seconds of reactive hyperemia compared with
baseline measurements after deflation of a cuff placed
around the forearm that had been inflated to 50 mm Hg
above systolic blood pressure for 5 minutes. Increase in
diameter after sublingual nitroglycerin spray (0.4 mg) was
used as a measure of endothelium-independent vasodila-
tion. The response of the vessel diameter to reactive hyper-
emia and nitroglycerin was expressed as percent change
relative to the diameter immediately before cuff inflation
and to the diameter immediately before drug administra-
tion, respectively. In our laboratory, intraobserver variabil-
ity for repeated measurements of resting arterial diameter is
0.01  0.02 mm. When reactive hyperemia studies are
performed on different days, the between-occasion, within-
patient difference for measurement of FMD is 1.5% 
0.7%. All drugs were discontinued for 18 hours or longer
before the study, which was carried out in the morning,
after an overnight fast, in a quiet room at a constant
temperature of 21°C  1°C. All subjects abstained from
smoking and intake of caffeine-containing food and bever-
ages for at least 12 hours before the study. Fasting venous
blood was obtained after nontraumatic venipuncture 15
minutes before FMD measurement. Plasma CRP was de-
termined with a highly sensitive (hs) assay (Dade Behring
Diagnostics,Marburg, Germany). Clottable fibrinogen was
estimated according to a functional assay (Clauss) on a
Behring BCS coagulation analyzer with Multifibren U
(Dade Behring Diagnostics). Total serum triglyceride, cho-
lesterol, and high-density lipoprotein-cholesterol concen-
trations were measured with commercially available kits.
Diagnostic criteria. A history of cardiovascular dis-
ease was considered positive when confirmed with hospital
records documenting CAD (previous myocardial infarc-
tion, or positive coronary angiogram or positive myocardial
scintigram), and carotid vessel disease (CVD; previous
stroke or ultrasound-proved stenosis greater than 50% in at
least one carotid artery). Hypertension was diagnosed if
systolic arterial pressure exceeded 140 mm Hg or diastolic
arterial pressure exceeded 90 mmHg, or if the patient used
antihypertensive drugs. Hyperlipidemia was diagnosed if
plasma total cholesterol concentration exceeded 240 mg/
dL, plasma triglyceride levels exceeded 200 mg/dL, or the
patient used lipid-lowering drugs. Diabetes mellitus was
diagnosed if plasma fasting glucose concentration exceeded
120 mg/dL or the patient used hypoglycemic agents. To
evaluate the relationship between FMD and atherosclerotic
burden, patients were classified as follows: patients with
unilateral PAD alone; patients with bilateral PAD alone;
patients with bilateral PAD plus 1 site, ie, atherosclerosis in
coronary or carotid arteries; and patients with bilateral PAD
plus 2 sites, ie, atherosclerosis in both coronary and carotid
arteries.
Statistical analysis. Data were analyzed with the t test
(normally distributed), Mann-Whitney U test (nonnor-
mally distributed), or 2 test (categorical variables). Corre-
lations were obtained with the Spearman method. Multi-
variate logistic regression analysis was used to assess which
variables were significantly related to impaired FMD. Data
are expressed as mean plus or minus standard deviation
(SD; normally distributed) or median plus [25th; 75th]
percentile (nonnormally distributed).
RESULTS
No woman in either the PAD or control group was
receiving hormone replacement therapy, and, except for
one patient with PAD, all were older than 60 years (Table
I). According to the diagnostic criteria, CADwas present in
45 (51%), and CVD was present in 24 (27%) of patients
with PAD. No control subject had a history of CAD or CVD.
Compared with healthy subjects, patients with PAD
had lower FMD (11.4% [9.3; 12.9] vs 7.3% [5.1; 9.5; P 
.01) but similar nitroglycerin-mediated vasodilation
(12.5% [10.0; 14.1] vs 11.8% [9.6; 13.1]). This confirms
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that impaired vasoreactivity in PAD depends exclusively on
endothelial dysfunction. Plasma levels of the inflammatory
marker hs-CRP were higher in patients than in control
subjects (2.8 mg/L [1.1; 7.4] vs 0.9 mg/L [0.5; 2.1]; P
.01), whereas fibrinogen levels were similar in the two
groups: 257 mg/dL [207; 334] in control subjects and
284 mg/dL [210; 404] in the PAD group.
To assess the relationship between FMD and several
determinants of endothelial dysfunction, we divided pa-
tients with PAD into two groups, using as an arbitrary
cutoff point an FMD value of 6.2%, ie, 5th percentile of
FMD in the control group. Thirty-six patients had FMD
less than 6.2%, and 52 had FMD greater than 6.2% (Table
II). Of interest, FMDwas still lower in the PAD group with
less impaired endothelial function than in the control group
(9.1% [7.7; 10.8] vs 11.4% [9.3; 12.9]; P  .01).
Relationship between FMD, classic risk factors, and
inflammatory markers. There was no difference in age,
sex, and prevalence of classic cardiovascular risk factors
between the two groups of patients categorized according
to FMD (Table II). Conversely, patients with greater en-
dothelial dysfunction had higher plasma levels of both
hs-CRP (P .01) and fibrinogen (P .01) compared with
patients with FMD greater than 6.2%. The association
between inflammatory markers and endothelial dysfunc-
tion was confirmed by the finding that FMD negatively
correlated with plasma levels of both hs-CRP (r0.501;
P .01) and fibrinogen (r0.559; P .01) (Fig 1). In
contrast, nitroglycerin-mediated vasodilation was unre-
lated to plasma levels of inflammatory markers (data not
shown). Also after adjustment for confounding factors
(age, sex, smoking habit, diabetes mellitus, hypertension,
hyperlipidemia), plasma levels of hs-CRP and fibrinogen
remained predictive of FMD  6.2%, ie, of greater endo-
thelial dysfunction (Table III, model 1). The same results
were obtained when women were removed from the PAD
and control groups (data not shown).
Relationship between FMD and ABI. Patients with
FMD less than 6.2% had significantly lower ABI than did
those with FMD greater than 6.2% (Table II). Moreover,
ABI was significantly, albeit weakly, related to FMD (r 
0.238; P  .05) but not to nitroglycerin-mediated vasodi-
lation (data not shown). ABI, when adjusted for age, sex,
and classic cardiovascular risk factors, remained indepen-
dently associated with greater endothelial dysfunction (Ta-
ble III, model 1). Stepwise multiple regression analysis
including ABI and plasma levels of hs-CRP and fibrinogen,
Table I. Clinical characteristics of control subjects and
patients with PAD
Control
subjects
(N  30)
Patients
with PAD
(N  88)
Age (y) 62  8 65  10
Sex (M/F) 27/3 81/7
Hypertension 6 (20) 48 (55)*
Systolic BP (mm Hg) 136  11 145  18*
Diastolic BP (mm Hg) 80  7 82  10
Smoking status
Current 5 (17) 46 (52)*
Former 10 (33) 35 (40)
Hyperlipidemia 4 (13) 48 (55)*
Cholesterolemia (mg/dL) 221  48 217  46
HDL-cholesterol (mg/dL) 43  8 41  9
Triglyceride level (mg/dL) 175  58 180  135
Diabetes mellitus 0 28 (32)*
Glycemia (mg/dL) 103  12 118  41*
Treatment
Antiplatelets 0 69 (78)*
ACE inhibitors 4 (13) 36 (41)*
Calcium antagonists 1 (3) 38 (43)*
-Blockers 1 (3) 11 (12)
Nitrates 0 30 (34)*
Statins 1 (3) 34 (39)*
Oral hypoglycemic agents 0 22 (25)*
Insulin 0 6 (7)
Numbers in parentheses represent percent.
BP, Blood pressure; HDL, high-density lipoprotein; ACE, angiotensin-
converting enzyme.
*P  .01 vs control subjects.
Table II. Characteristics of patients with different
degrees of brachial artery endothelium-dependent, flow-
mediated dilation
FMD  6.2%
(N  52)
FMD  6.2%
(N  36)
Age (y) 63  11 67  9
Sex (M/F) 48/4 33/3
Hypertension 25 (48) 23 (64)
Systolic BP (mm Hg) 145  19 144  17
Diastolic DBP (mm Hg) 82  10 83  10
Smoking
Current 29 (56) 17 (47)
Former 19 (36) 16 (44)
Hyperlipidemia 28 (54) 20 (55)
Cholseterolemia (mg/dL) 218  50 216  39
HDL cholesterol (mg/dL) 40  10 43  8
Triglyceridelevel (mg/dL) 181  134 178  104
Diabetes mellitus 17 (33) 11 (31)
Glycemia (mg/dL) 120  39 115  41
Coronary artery disease 26 (50) 19 (53)
Carotid vascular disease 13 (25) 11 (30)
Previous MI 23 (44) 15 (42)
ABI 0.72  0.15 0.62  0.16*
hs-CRP (mg/L) 1.6 [0.6; 5.4] 6.0 [2.8; 7.7]*
Fibrinogen (mg/dL) 200 [177; 293] 374 [273; 453]*
Treatment
Antiplatelets 40 (77) 29 (80)
ACE inhibitors 22 (42) 14 (39)
Calcium antagonists 21 (40) 17 (47)
-Blockers 7 (13) 4 (11)
Nitrates 17 (33) 13 (36)
Statins 19 (37) 15 (42)
Oral hypoglycemic agents 13 (25) 9 (25)
Insulin 4 (8) 2 (6)
Numbers in parentheses represent percent.
Numbers in brackets represent 25th and 75th percentile.
FMD, Flow-mediated dilation; BP, blood pressure; HDL, high-density
lipoprotein;MI, myocardial infarction; ABI, ankle/brachial index; hs-CRP,
high-sensitivity C-reactive protein; ACE, angiotension-converting enzyme.
*P  .01 vs patients with FMD 6.2%.
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ie, covariates that showed significant group differences at
univariate analysis, indicated that each of the three variables
was independently associated with FMD less than 6.2%
(Table III, model 2).
Relationship between FMD and atherosclerotic
burden. In the group of patients with FMD greater than
6.2%, 13 patients (25%) had isolatedmonolateral PAD, and
2 patients (4%) had widespread atherosclerosis, ie, bilateral
PAD plus 2 sites (Table IV). In the group with FMD less
than 6.2%, 4 patients (11%) had isolated monolateral PAD,
and 3 patients (8%) had widespread atherosclerosis . Statis-
tical analysis did not show group differences.
DISCUSSION
Impaired endothelial function, measured as reduced
brachial artery FMD, has been demonstrated in PAD.16-18
In our series, 41% of patients had FMD lower than the 5th
percentile of the control population. Because brachial ar-
tery endothelial function is a measure of systemic vascula-
ture status and a predictor of cardiovascular events,14,15 our
results are consistent with the finding that a large propor-
tion of patients with PAD are at high cardiovascular risk.1-4
The main purpose of this study was to investigate the
relationship between endothelial dysfunction in PAD and
variables potentially able to alter homeostatic properties of
endothelial cells. Cardiovascular risk factors impair endo-
thelial function even in the absence of clinical evidence of
cardiovascular disease.10 However, hyperlipidemia, hyper-
tension, smoking, and diabetes mellitus were distributed
equally between patients with FMD less than 6.2% and
those with better endothelial function. Conversely, plasma
levels of hs-CRP and fibrinogen, two markers of inflamma-
tion with key roles in endothelial dysfunction,7 differed
significantly between the two subgroups of patients. Both
markers negatively correlated with FMD; thus patients with
the highest plasma levels of hs-CRP and fibrinogen had the
lowest FMD values. Although correlation coefficients pro-
vide no information on cause and effect, our findings are
consistent with the hypothesis that inflammation contrib-
utes to endothelial dysfunction. Of interest, in patients with
CAD, normalization of CRP levels parallels improvement
in endothelial function.11 In our study, the association
between reduced FMD and high levels of CRP and fibrin-
ogen remained after adjustment for sex, age, and classic risk
Correlation of brachial artery flow-mediated dilation (FMD) with
plasma levels of both high-sensitivity C-reactive protein and fibrin-
ogen.
Table III. Association of ankle/brachial index, high-
sensitivity C-reactive protein, and fibrinogen with brachial
artery flow-mediated dilation 6.2%
Wald 2
(model I)
Wald 2
(model 2)
ABI 7.80* 7.29*
hs-CRP 4.55* 3.79†
Fibrinogen 6.01* 7.29†
ABI, Ankle-brachial index; hs-CRP, high sensitivity C-reactive protein;
FMD, flow-mediated dilation.
Model 1 tests associations of FMD 6.2% with ABI, hs-CRP, and fibrino-
gen individually, adjusted for age, sex, smoking habit, hyperlipidemia,
hypertension, and diabetes mellitus. Model 2 includes the three variables
simultaneously.
*P  .01.
†P  .05.
Table IV. Atherosclerotic burden in patients with
different degrees of brachial artery endothelium-
dependent, flow-mediated dilation
FMD
6.2%
(N  52)
FMD
6.2%
(N  36)
n % n %
Monolateral isolated PAD (n  17) 13 25 4 11
Bilateral isolated PAD (n  14) 7 13 7 19
Bilateral PAD  1 site (n  23) 13 25 10 28
Bilateral PAD  2 sites (n  5) 2 4 3 8
FMD, Flow-mediated dilation; PAD, peripheral arterial disease.
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factors. This coincides with the observation that in PAD the
association between impaired FMD and elevated levels of
other inflammatory markers, ie, circulatory forms of inter-
cellular adhesion molecule–1 and vascular cell adhesion
molecule–1, is unrelated to traditional risk factors.17 We
found no difference in prevalence of classic risk factors
between patients with worse endothelial function and those
with FMD greater than 6.2%. Neunteufl et al21 found that
patients with angiographically proved CAD have greater
brachial artery endothelial dysfunction than do those with
similar risk profile but with smooth coronary arteries. To-
gether these findings support the concept that the influence
of overt atherosclerosis exceeds that of traditional risk
factors in affecting endothelial function. Consequently,
PAD severity and total atherosclerotic burden could be
other factors that influence the degree of endothelial dys-
function. In effect, patients with FMD less than 6.2% had
lower ABI than those with FMD greater than 6.2%, even
after adjustment for age, sex, and classic cardiovascular risk
factors. Oxidative stress, a major determinant of endothelial
dysfunction,22 may be involved in the mechanism linking
PAD severity and endothelial function.We did not measure
oxidative stress; however, lipid peroxide levels are increased
and antioxidant vitamin C levels are decreased in PAD.23-25
It is conceivable that the lower the ABI, and thus the more
severe the ischemic disease in the leg, the greater the
oxidative stress and consequently the endothelial dysfunc-
tion. On the other hand, oxidative stress and endothelial
dysfunction are associated with risk factors for PAD, also in
the absence of vascular diseases.26-28 For example, oxida-
tive stress is one of the first abnormalities detected in
children with diabetes, in tandem with impaired endothe-
lial function.29 Therefore increased oxidative stress could
be the cause rather than the consequence of more severe
PAD. The cross-sectional nature of this study does not
allow us to clarify this point. In any event, the two hypoth-
eses are not mutually exclusive. Oxidative stress and endo-
thelial dysfunction secondary to cardiovascular risk factors
could favor development of PAD in susceptible persons,
and PAD would contribute to further deterioration in
endothelial function via increased oxidative stress.
In multivariate analysis including ABI, hs-CRP, and
fibrinogen, we found that all three variables were indepen-
dently related to FMD less than 6.2%. In addition to being
a marker of inflammation, CRP, which induces expression
of adhesion molecules and chemokines in human endothe-
lial cells,30,31 could amplify the inflammatory process and
thus endothelial dysfunction. Similarly, fibrinogen may
contribute to vascular dysfunction through its proteolytic
degradation products,32,33 which may be found in athero-
ma.34,35 Of interest, although in comparison of patients
with PAD and control subjects endothelial dysfunction
seemed to be unrelated to plasma levels of fibrinogen, in
patients with PAD this inflammatory marker was signifi-
cantly associated with reduced FMD. This apparent incon-
sistency may be explained by a synergistic action of given
levels of fibrinogen with another factor present in patients
with PADbut not in control subjects. This additional factor
could be damaged endothelium, which when infiltrated by
high levels of fibrinogen, as in our patients with FMD less
than 6.2%, deteriorates even further.32-37
Compared with what we observed in patients with
FMD greater than 6.2%, in the subgroup with FMD less
than 6.2% the prevalence of isolated monolateral PAD was
less than half and the prevalence of widespread atheroscle-
rosis, ie, bilateral PAD plus 2 sites, was double. This sug-
gests that FMD is related to atherosclerotic burden. The
lack of difference in the extent of atherosclerosis between
the two groups of patients could be due to the relatively
small sample size.
Study limitations. Although treatments were discon-
tinued at least 18 hours before the study, we cannot exclude
the premise that the long-lasting effect of drugs such as
angiotensin-converting enzyme inhibitors and calcium an-
tagonists may have beneficially influenced FMD. However,
because the number of subjects taking these drugs was
much higher in the PAD group, these treatments did not
influence the finding that patients with PAD have lower
FMD than control subjects do. At best, longer drug dis-
continuation would have implied even greater FMD reduc-
tion in patients with PAD. In contrast, there was no differ-
ence in drug distribution between the two groups of
patients, categorized according to FMD (Table II). On the
other hand, because of the broad spectrum of drugs and
doses administered, we were unable to examine the inter-
action between treatment status and FMD.
A second limitation of the study is that myocardial
scintigraphy was not performed in the control group. This
may imply underestimation of the prevalence of CAD, a
condition, however, associated with reduced brachial artery
FMD.13 Therefore the lack of this information does not
confer bias.
Finally, the measure we used to quantify atherosclerotic
burden is less objective than angiographic score. However,
at the time of the study, the clinical condition of our
patients did not require angiography, and thus the extent of
atherosclerotic disease was quantified according to the
method previously used by Blann et al.38
CONCLUSIONS
A large proportion of patients with PAD have severe
endothelial dysfunction that results from a variety of fac-
tors. It is interesting that lowABI and high levels of hs-CRP
and fibrinogen, which were independently associated with
reduced FMD, are also significant predictors of cardiovas-
cular events in patients with PAD.2,4-6 It is uncertain
whether oxidative stress and inflammation per se are mod-
ifiable risk factors. However, preliminary data suggest that
preventive therapy with angiotensin-converting enzyme
inhibitors and statins may work through mechanisms that
counteract oxidative stress and inflammation.39-42 There-
fore our data support the need for studies to assess whether
these therapies, in addition to modification of classic risk
factors, may help to improve endothelial function and
reduce cardiovascular risk in PAD.
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